14 October 2021  
EMA/CHMP/565583/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion 1 (post authorisation) 
Lenvima 
lenvatinib 
On 14 October 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Lenvima. The marketing authorisation holder for this medicinal product is Eisai GmbH. 
The CHMP adopted a new indication as follows: 2 
Differentiated Thyroid Carcinoma (DTC) 
Lenvima as monotherapy is indicated for the treatment of adult patients with progressive, locally 
advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), 
refractory to radioactive iodine (RAI). 
Hepatocellular Carcinoma (HCC) 
Lenvima as monotherapy is indicated for the treatment of adult patients with  
advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior  systemic 
therapy (see section 5.1). 
Endometrial Carcinoma (EC) 
Lenvima in combination with pembrolizumab is indicated for  the treatment of adult 
patients with advanced or recurrent endometrial carcinoma (EC) who have disease 
progression on or following prior treatment with a platinum-containing therapy in any 
setting and are not candidates for curative surgery or radiation. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of  positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days f rom adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Am sterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
